Invitrocue is a world-class innovative life sciences company specializing in groundbreaking 3D cell-based models derived from liver and tumor tissues. Our mission is to create a healthier society by providing patients with the best possible care. As a partner for personalized oncology, we develop and commercialize technologies that enable in vitro drug screenings on Patient-Derived Organoids (PDOs) from solid cancers.

These screenings provide oncologists with crucial information for better directing patient therapy and personalized treatment. By imparting valuable knowledge to the industry, we contribute to the development of better, faster, and more affordable disease treatments. Our technology is derived from Singapore's Agency for Science, Technology and Research (A*STAR) and has been successfully developed into various commercial services.

These include in vitro Human Liver models for drug toxicology testing, in vitro Human NASH (Fatty Liver) model, in vitro Human Liver infection models, in vitro Human Respiratory models, in vitro Human Oncology Organoids, and in vivo Humanized Immune Organoid. Our partnerships with leading global Cancer centers and pharmaceutical companies demonstrate our commitment to advancing cancer treatment. Headquartered in Singapore, Invitrocue operates in Germany, Spain, Brazil, Australia, China, and Hong Kong.

Reach out to our team to learn more about how we can help you. Contact us today!